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Background
In previous studies of protease inhibitor (PI) monotherapy, patients with higher nadir CD4 counts, baseline HIV RNAB1 copy/mL
and high adherence to treatment have been most likely to show sustained HIV RNA suppressionB50 copies/mL.
Methods
In the MONET trial, 256 patients with HIV RNA B50 copies/mL at screening switched to DRV/r 800/100 mg once daily, either as
monotherapy (n127) or with 2 NRTIs (n129). HIV RNA results were classified as eitherB5 (no detection), 549 (virus
detected under quantification limit) or  50 copies/mL. Treatment failure was defined as two consecutive HIV RNA levels  50
copies/mL (TLOVR) by Week 144, or discontinuation of study drugs. Additional analyses were conducted (i) excluding
discontinuations for adverse events or other reasons (ii) including patients who intensified with NRTIs. Multivariate logistic
regression was used to identify factors predictive of treatment failure by Week 144.
Results
By Week 144, the percentage of patients with HIV RNA B50 copies/mL (ITT,TLOVR, SwitchFailure) was 69% versus 75% in the
DRV/r monotherapy and triple therapy arms respectively. In the Switch Included analysis, HIV RNA B50 copies/mL was 84.0%
versus 83.5% in the DRV/r monotherapy and triple therapy arms respectively. In the multivariate analysis for the TLOVR
endpoint, positive HCV serology correlated with treatment failure (odds ratio [OR]2.44, 95% CI 1.205.00). In the analysis
including only virological endpoints, both positive HCV serology (OR2.77, 95% CI 1.18-6.67) and baseline HIV RNA  5 copies/
mL (OR2.71, 95% CI 1.21-6.08) predicted treatment failure. In the Switch Included analysis, only HIV RNA  5 copies/mL was
predictive of treatment failure (OR2.78, 95% CI 1.286.01). Nadir CD4 count and prior PI use were not predictive of treatment
failure in any analysis. In the ITT TLOVR analysis, the response rates in the DRV/r monotherapy arm at Week 144 were 79%
(66/84) for HCV-ve patients with baseline HIV RNA B5 copies/mL, 63% (12/19) for HCV-ve patients with baseline HIV RNA  5
copies/mL, 47% (9/19) for HCVve patients with baseline HIV RNAB5 copies/mL and 20% (1/5) for HCVve patients with
baseline HIV RNA 5 copies/mL.
Conclusions
In the MONET trial, patients without HCV co-infection (based on serology), and with baseline HIV RNA B5 copies/mL by the
Roche Amplicor assay (i.e. no virus detected) were most likely to show sustained HIV RNA suppressionB50 copies/mL on DRV/r
monotherapy.
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